Pathways of Induction of Peroxiredoxin I Expression in Osteoblasts

Baojie Li,Tetsuro Ishii,Choon Ping Tan,Jae‐Won Soh,Stephen P. Goff

DOI: https://doi.org/10.1074/jbc.m111443200

2002-01-01

Abstract:Peroxiredoxin I (Prx I) is an oxidative stress-inducible antioxidant protein with thioredoxin peroxidase activity. Here we report that the levels of Prx I mRNA and protein are dramatically increased in a murine osteoblast cell line, MC3T3-E1, by treatment with sodium arsenate. We further studied the signaling pathways that control the induction of Prx I expression. The treatment of osteoblasts with arsenate activated ERK1/2, JNK, and p38 MAPK. Pre-treating cells with inhibitors of p38 MAPK abolished the induction of Prx I protein but had minimal effect on the induction of Prx I mRNA, suggesting that p38 MAPK activity was required for post-transcriptional regulation. The inhibition of ERK1 and ERK2 had no effect on the induction of Prx I expression. Furthermore, rottlerin, an inhibitor of protein kinase Cδ (PKCδ) and calmodulin kinase III, abrogated the up-regulation at both protein and mRNA levels. Staurosporine and Go6983, inhibitors for PKC, also inhibited the induction of Prx I, suggesting that protein kinase Cδ is required for the induction by arsenate. PKCδ was activated by arsenate treatment by in vitro kinase assays. The inhibition of PKCδ by rottlerin did not affect the activation of p38 MAPK by arsenate. These results suggest that there are two separate signaling pathways involved in the up-regulation of Prx I protein in response to arsenate, PKCδ required for transcriptional activation and p38 MAPK required for post-transcriptional regulation.